Effects of Chemotherapy and Radiation Therapy on Visual Acuity and Color Vision in Cancer Patients
Main Article Content
Abstract
Background: Anticancer therapies may be accompanied by ocular complications that can affect visual function. Objective: To assess visual acuity and color vision among cancer patients receiving chemotherapy, radiation therapy, or combined treatment and to describe visual findings according to treatment type and duration. Methods: This cross-sectional descriptive study included 150 cancer patients attending the Oncology Department of Combined Military Hospital, Rawalpindi, from March to April 2019. Participants were selected through purposive sampling. Visual acuity was assessed monocularly using a Snellen chart, and color vision was evaluated using Ishihara pseudo-isochromatic plates. Descriptive statistics and chi-square tests were used for analysis. Results: Of 150 participants, 92 (61.3%) were male. Chemotherapy alone was received by 82 (54.7%), combined therapy by 48 (32.0%), and radiation therapy alone by 20 (13.3%). Visual acuity below 6/9 increased across longer treatment-duration categories in the right eye from 26.3% at 1–6 months to 66.7% at 3–4 years and in the left eye from 26.3% to 75.0%. Treatment duration was associated with reduced visual acuity in the right (p=0.001) and left eyes (p<0.001), whereas treatment modality was not significantly associated with reduced acuity. Conclusion: Visual acuity impairment was common among treated cancer patients and was more frequent with longer treatment duration, while no significant difference was demonstrated according to treatment modality
Article Details
Issue
Section

This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1. Fraunfelder FT, Meyer SM. Ocular toxicity of antineoplastic agents. Ophthalmology. 1983;90(1):1–3. doi:10.1016/S0161-6420(83)34600-5.
2. Archer DB, Amoaku WMK, Gardiner TA. Radiation retinopathy—clinical, histopathological, ultrastructural and experimental correlations. Eye (Lond). 1991;5:239–251. doi:10.1038/eye.1991.39.
3. al-Tweigeri T, Nabholtz JM, Mackey JR. Ocular toxicity and cancer chemotherapy. A review. Cancer. 1996;78(7):1359–1373. doi:10.1002/(SICI)1097-0142(19961001)78:7<1359::AID-CNCR1>3.0.CO;2-G.
4. Schmid KE, Kornek GV, Scheithauer W, Binder S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51(1):19–40. doi:10.1016/j.survophthal.2005.11.001.
5. Omoti AE, Omoti CE. Ocular toxicity of systemic anticancer chemotherapy. Pharm Pract (Granada). 2006;4(2):55–59.
6. Stoicescu EA, Iancu RC, Popa Cherecheanu A, Iancu G. Ocular adverse effects of anti-cancer chemotherapy. J Med Life. 2023;16(6):818–821. doi:10.25122/jml-2023-0041.
7. Bader A, Begemann M, Al-Obaidi A, Habib MH, Anwer F, Raza S. Ocular complications of antineoplastic therapies. Future Sci OA. 2023;9(7). doi:10.2144/fsoa-2022-0081.
8. Chiang JCB, Zahari I, Markoulli M, Krishnan AV, Park SB, Semmler A, et al. The impact of anticancer drugs on the ocular surface. Ocul Surf. 2020;18(3):403–417. doi:10.1016/j.jtos.2020.03.008.
9. Kunkler AL, Binkley EM, Mantopoulos D, Hendershot AJ, Ohr MP, Kendra KL, et al. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics. Graefes Arch Clin Exp Ophthalmol. 2019;257(8):1771–1781.
10. Li Y, Li Y, Li J, Pi G, Tan W. Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review. Onco Targets Ther. 2014;7:1361–1366.
11. Wilding G, Caruso R, Lawrence TS, Ostchega Y, Ballintine EJ, Young RC. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol. 1985;3(12):1683–1689.
12. Caraceni A, Martini C, Spatti G, Thomas A, Onofrj M. Recovering optic neuritis during systemic cisplatin and carboplatin chemotherapy. Acta Neurol Scand. 1997;96(4):260–261.
13. Pippitt CH Jr, Muss HB, Homesley HD, Jobson VW. Cisplatin-associated cortical blindness. Gynecol Oncol. 1981;12:253–255.
14. Cohen RJ, Cuneo RA, Cruciger MP, Jackman AE. Transient left homonymous hemianopsia and encephalopathy following treatment of testicular carcinoma with cisplatinum, vinblastine, and bleomycin. J Clin Oncol. 1983;1(6):392–393.
15. Rankin EM, Pitts JF. Ophthalmic toxicity during carboplatin therapy. Ann Oncol. 1993;4(4):337–338.
16. Kwan AS, Sahu A, Palexes G. Retinal ischemia with neovascularization in cisplatin-related retinal toxicity. Am J Ophthalmol. 2006;141(1):196–197.
17. Kende G, Sirkin SR, Thomas PR, Freeman AI. Blurring of vision: a previously undescribed complication of cyclophosphamide therapy. Cancer. 1979;44(1):69–71. doi:10.1002/1097-0142(197907)44:1<69::AID-CNCR2820440113>3.0.CO;2-O.
18. Stevens A, Spooner D. Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early-stage breast cancer. Clin Oncol (R Coll Radiol). 2001;13(6):438–440.
19. Shingleton BJ, Bienfang DC, Albert DM, Ensminger WD, Chandler WF, Greenberg HS. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol. 1982;100(11):1766–1772.
20. Capri G, Munzone E, Tarenzi E, Fulfaro F, Gianni L, Caraceni A, et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst. 1994;86(14):1099–1101.
21. Kord Valeshabad A, Mieler WF, Setlur V, Thomas M, Shahidi M. Posterior segment toxicity after gemcitabine and docetaxel chemotherapy. Optom Vis Sci. 2015;92(5)–e113.
22. Jack MK, Hicks JD. Ocular complications in high-dose chemoradiotherapy and marrow transplantation. Ann Ophthalmol. 1981;13(6):709–711.
23. Lovett EA Jr, Fan J, Williams BK Jr, Di Nicola M. Update on diagnosis and management of radiation retinopathy. Curr Opin Ophthalmol. 2025;36(3):167–176. doi:10.1097/ICU.0000000000001126.